- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04344886
Optimization and Individualization of Diagnostic Scintigraphy Protocol and Minimally Invasive Radio-guided Parathyroid Surgery
December 6, 2022 updated by: University Hospital Ostrava
Optimization and Individualization of Diagnostic Scintigraphy Protocol and Minimally Invasive Radio-guided Parathyroid Surgery Using Quantitative Analysis of Scintigraphy Results on Hybrid SPECT-CT Imaging
The radio-guided technique offers both help with in-vivo identification and ex-vivo confirmation of parathyroid adenoma.
In-vivo accuracy is most important but its results are not satisfactory.
The aim of this study was to evaluate if there is a beneficial effect of individualized timing of surgery using preoperative multi-phase 99mTc-MIBI single-photon emission computed tomography (SPECT)/CT on in-vivo characteristics of minimally invasive radio-guided parathyroidectomy.
Study Overview
Status
Completed
Detailed Description
Despite the relatively accurate preoperative topographic information, minimally invasive parathyroid surgery can still be very challenging, especially in the case of small adenoma in ectopic localization.
Radioguided technique offers both help with in-vivo identification and ex-vivo confirmation of adenoma.
Excellent ex-vivo radio guidance results are referred.
But, in-vivo accuracy is most important but its results are not satisfactory.
The aim of this study was to evaluate if there is a beneficial effect of individualized timing of surgery using preoperative multi-phase 99mTc-MIBI single-photon emission computed tomography (SPECT)/CT on in-vivo characteristics of minimally invasive radio-guided parathyroidectomy.
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Moravian-Silesian Region
-
Ostrava, Moravian-Silesian Region, Czechia, 70852
- University Hospital Ostrava
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult patients
- No history of thyroid or parathyroid surgery
- Diagnosis of primary hyperparathyroidism
- Indication for 99mTc-MIBI SPECT/CT examination
Exclusion Criteria:
- Minor patients
- Negative SPECT/CT findings
- Patients refusing surgery
- Previous combined surgery on the thyroid gland
- Patients in high risk of general anesthesia
- Patients who do not undergo surgery in the recommended time span
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Conventional (dual-phase) SPECT/CT
Adult patients with primary hyperparathyroidism undergoing conventional (dual-phase) SPECT/CT (after 10 and 150 minutes) and conventional minimally-invasive radio-guided parathyroidectomy in a time span 2-3 hours from radionuclide administration.
|
Conventional (dual-phase) SPECT/CT (after 10 and 150 minutes)
Conventional minimally invasive radio-guided parathyroidectomy in a time span of 2-3 hours from radionuclide administration
|
Experimental: Multi-phase SPECT/CT
Adult patients with primary hyperparathyroidism undergoing multi-phase SPECT/CT (after 10, 90, 150, 210 minutes) and individualized minimally-invasive radio-guided parathyroidectomy performed in a recommended time span based on standardized uptake value calculation.
|
Multi-phase SPECT/CT (after 10, 90, 150, 210 minutes)
Individualized minimally-invasive radio-guided parathyroidectomy performed in a recommended time span based on standardized uptake value calculation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Success of surgery (%)
Time Frame: 3 months
|
Surgery was considered successful if there were lowering of parathyroid hormone serum level and calcemia to normal and histological confirmation of parathyroid gland adenoma/ hyperplasia.
|
3 months
|
In-vivo sensitivity (%)
Time Frame: 3 months
|
Calculated from number of true positive, false positive, true negative and false negative cases identified by gamma probe during surgery.
The parathyroid tissue was considered pathologic when the in-vivo radioactive counting was at least 1.15 times more than the background.
|
3 months
|
In-vivo specificity (%)
Time Frame: 3 months
|
Calculated from number of true positive, false positive, true negative and false negative cases identified by gamma probe during surgery.
The parathyroid tissue was considered pathologic when the in-vivo radioactive counting was at least 1.15 times more than the background.
|
3 months
|
In-vivo accuracy (%)
Time Frame: 3 months
|
Calculated from number of true positive, false positive, true negative and false negative cases identified by gamma probe during surgery.
The parathyroid tissue was considered pathologic when the in-vivo radioactive counting was at least 1.15 times more than the background.
|
3 months
|
Ex-vivo sensitivity (%)
Time Frame: 3 months
|
Calculated from number of true positive, false positive, true negative and false negative cases identified by gamma probe during surgery.
Radioactive ex-vivo counts in adenoma/ hyperplastic parathyroid gland greater than 20% of background was used as cutpoint for cure.
|
3 months
|
Ex-vivo specificity (%)
Time Frame: 3 months
|
Calculated from number of true positive, false positive, true negative and false negative cases identified by gamma probe during surgery.
Radioactive ex-vivo counts in adenoma/ hyperplastic parathyroid gland greater than 20% of background was used as cutpoint for cure.
|
3 months
|
Ex-vivo accuracy (%)
Time Frame: 3 months
|
Calculated from number of true positive, false positive, true negative and false negative cases identified by gamma probe during surgery.
Radioactive ex-vivo counts in adenoma/ hyperplastic parathyroid gland greater than 20% of background was used as cutpoint for cure.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Operating time (minutes)
Time Frame: Duration of surgery
|
The operating time will be measured and recorded.
|
Duration of surgery
|
Pathological parathyroid gland volume (ml)
Time Frame: Duration of surgery
|
The pathological parathyroid gland volume in millilitres will be measured and recorded.
|
Duration of surgery
|
Pathological parathyroid gland localisation (ectopic x eutopic)
Time Frame: Duration of surgery
|
The pathological parathyroid gland localisation (ectopic x eutopic) will be recorded.
|
Duration of surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Vladimír Dedek, MD,PhD, University Hospital Ostrava
- Principal Investigator: Martin Formánek, MD,PhD, University Hospital Ostrava
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2016
Primary Completion (Actual)
November 30, 2020
Study Completion (Actual)
December 31, 2020
Study Registration Dates
First Submitted
April 9, 2020
First Submitted That Met QC Criteria
April 9, 2020
First Posted (Actual)
April 14, 2020
Study Record Updates
Last Update Posted (Estimate)
December 7, 2022
Last Update Submitted That Met QC Criteria
December 6, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FNO-ENT-Parathyroid_adenoma
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
Individual participant data will be made available to other researchers upon request.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Hyperparathyroidism
-
Postgraduate Institute of Medical Education and...UnknownPrimary Hyperparathyroidism (PHPT)India
-
Nantes University HospitalCompleted
-
Rambam Health Care CampusWithdrawnMultigland Disease in Primary HyperparathyroidismIsrael
-
Sheffield Teaching Hospitals NHS Foundation TrustCompletedTotal Thyroidectomy | Bilateral Neck Exploration for Primary HyperparathyroidismUnited Kingdom
-
Nantes University HospitalInstitut National de la Santé Et de la Recherche Médicale, FranceRecruiting
-
Brigham and Women's HospitalCompletedPrimary HyperparathyroidismUnited States
-
University Hospital Inselspital, BerneCompletedPrimary HyperparathyroidismSwitzerland
-
EFSTATHIOS CHRONOPOULOSCompletedPrimary Hyperparathyroidism
-
M.D. Anderson Cancer CenterUnknownPrimary HyperparathyroidismUnited States
-
Assistance Publique - Hôpitaux de ParisUnknownPrimary Hyperparathyroidism
Clinical Trials on Conventional (dual-phase) SPECT/CT
-
Radboud University Medical CenterRecruiting
-
Yale UniversityUniversity of Illinois at Urbana-ChampaignRecruitingDiabetes Mellitus | Peripheral Arterial DiseaseUnited States
-
Rambam Health Care CampusCompleted
-
Central Hospital, Nancy, FranceCompleted
-
Tomsk National Research Medical Center of the Russian...Uppsala UniversityCompletedBreast Cancer FemaleRussian Federation
-
Lawson Health Research InstituteUniversity of Western Ontario, CanadaTerminated
-
BAMF HealthRecruitingMetastatic Castration-resistant Prostate CancerUnited States
-
Rambam Health Care CampusCompleted
-
Martini Hospital GroningenRecruitingOsteoarthritis | Osteoarthritis AnkleNetherlands
-
Mayo ClinicRecruitingFocus of Study is Comparison of 2 Types of Gamma CamerasUnited States